Cigna pharmacy January 2022 clinical update

At Cigna, plan affordability is always top of mind. Our latest comprehensive drug review and actions span across medical and pharmacy drug utilization to help promote appropriate and cost-effective medication use and expanded choice. These updates intend to achieve savings and improved medication adherence for customers – as well as a $2.83 per member per month (PMPM) average projected savings for clients.¹

Effective January 2022, wide-ranging enhancements will affect:

Specialty drugs – some covered under the medical benefit and some under pharmacy
Non-specialty drugs – Synthroid (hypothyroidism) will move to a non-covered status to encourage the use of generics
Egregiously priced drugs
Non-Food and Drug Administration (FDA)-approved drugs
Preventive drugs
Improved drug access/costs for conditions like high cholesterol, asthma and obesity
Continuous glucose monitor (CGM) transmitters

Affected customers (and their providers) will receive notification letters and emails in early October 2021. Reminders will release in November 2021 and again in January 2022.

LEARN MORE:
For a summary of Cigna's January 2022 formulary changes, click here.

For clients using Standard, Performance, Value or Advantage formularies. Cigna National Book of Business pricing analysis estimating value of January 2022 drugs under medical benefit, under pharmacy benefit (formulary) and UM changes (for clients that adopt Cigna’s UM packages or Cigna specialty UM). Results may vary.